Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 2
2007 2
2008 3
2009 5
2010 2
2011 3
2012 3
2013 4
2014 11
2015 4
2016 5
2017 14
2018 11
2019 15
2020 19
2021 23
2022 25
2023 24
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Results by year

Filters applied: . Clear all
Page 1
Overactive bladder induces transient hypertension.
Torimoto K, Matsumoto Y, Gotoh D, Morizawa Y, Miyake M, Samma S, Tanaka N, Hirayama A, Fujimoto K. Torimoto K, et al. BMC Res Notes. 2018 Mar 27;11(1):196. doi: 10.1186/s13104-018-3317-6. BMC Res Notes. 2018. PMID: 29580270 Free PMC article.
Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer.
Miyake M, Oda Y, Owari T, Iida K, Ohnishi S, Fujii T, Nishimura N, Miyamoto T, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: torimoto k. Cancer Sci. 2023 Mar;114(3):1118-1130. doi: 10.1111/cas.15666. Epub 2022 Nov 30. Cancer Sci. 2023. PMID: 36398663 Free PMC article.
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
Miyake M, Shimizu T, Oda Y, Tachibana A, Ohmori C, Itami Y, Kiba K, Tomioka A, Yamamoto H, Ohnishi K, Nishimura N, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: torimoto k. Jpn J Clin Oncol. 2023 Mar 7;53(3):253-262. doi: 10.1093/jjco/hyac186. Jpn J Clin Oncol. 2023. PMID: 36484294
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Among authors: torimoto k. Jpn J Clin Oncol. 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. Jpn J Clin Oncol. 2024. PMID: 38061911
[URETHROPLASTY FOR COMPLICATED ANTERIOR URETHRAL STRICTURES].
Aoki K, Hori S, Morizawa Y, Nakai Y, Miyake M, Anai S, Torimoto K, Yoneda T, Tanaka N, Yoshida K, Fujimoto K. Aoki K, et al. Among authors: torimoto k. Nihon Hinyokika Gakkai Zasshi. 2016;107(4):227-232. doi: 10.5980/jpnjurol.107.227. Nihon Hinyokika Gakkai Zasshi. 2016. PMID: 29070735 Free article. Japanese.
157 results